D.J. St. Germain’s Novo Nordisk NVO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $2.89M | Buy |
78,744
+211
| +0.3% | +$10K | 0.11% | 112 |
|
|
2025
Q4 | $4M | Sell |
78,533
-808
| -1% | -$41.3K | 0.16% | 105 |
|
|
2025
Q3 | $4.4M | Sell |
79,341
-444
| -0.6% | -$26K | 0.18% | 99 |
|
|
2025
Q2 | $5.51M | Buy |
79,785
+45
| +0.1% | +$3.06K | 0.24% | 85 |
|
|
2025
Q1 | $5.54M | Sell |
79,740
-221
| -0.3% | -$18.3K | 0.26% | 88 |
|
|
2024
Q4 | $6.88M | Sell |
79,961
-896
| -1% | -$96.9K | 0.31% | 81 |
|
|
2024
Q3 | $9.63M | Sell |
80,857
-1,982
| -2% | -$264K | 0.44% | 67 |
|
|
2024
Q2 | $11.8M | Sell |
82,839
-1,609
| -2% | -$213K | 0.57% | 55 |
|
|
2024
Q1 | $10.8M | Sell |
84,448
-1,699
| -2% | -$202K | 0.53% | 60 |
|
|
2023
Q4 | $8.91M | Sell |
86,147
-1,333
| -2% | -$132K | 0.46% | 65 |
|
|
2023
Q3 | $7.96M | Sell |
87,480
-146,328
| -63% | -$12.9M | 0.45% | 67 |
|
|
2023
Q2 | $18.9M | Buy |
+233,808
| New | +$19.1M | 1% | 27 |
|
|
2022
Q4 | $51.4K | Sell |
265,460
-6,972
| -3% | -$409K | 0.02% | 160 |
|
|
2022
Q3 | $15.2M | Hold |
272,432
| – | – | 1% | 27 |
|
|
2022
Q2 | $15.2M | Sell |
272,432
-6,168
| -2% | -$342K | 1% | 27 |
|
|
2022
Q1 | $15.5M | Sell |
278,600
-2,638
| -0.9% | -$135K | 0.87% | 37 |
|
|
2021
Q4 | $15.7M | Sell |
281,238
-11,936
| -4% | -$647K | 0.87% | 35 |
|
|
2021
Q3 | $14.1M | Sell |
293,174
-13,528
| -4% | -$654K | 0.87% | 40 |
|
|
2021
Q2 | $12.8M | Sell |
306,702
-7,276
| -2% | -$282K | 0.81% | 41 |
|
|
2021
Q1 | $10.6M | Sell |
313,978
-2,534
| -0.8% | -$90.3K | 0.72% | 43 |
|
|
2020
Q4 | $11.1M | Sell |
316,512
-4,460
| -1% | -$154K | 0.79% | 40 |
|
|
2020
Q3 | $11.1M | Sell |
320,972
-7,340
| -2% | -$245K | 0.9% | 36 |
|
|
2020
Q2 | $10.7M | Sell |
328,312
-12,712
| -4% | -$406K | 0.94% | 37 |
|
|
2020
Q1 | $10.3M | Sell |
341,024
-43,124
| -11% | -$1.28M | 1.01% | 34 |
|
|
2019
Q4 | $11.1M | Sell |
384,148
-2,056
| -0.5% | -$56.9K | 0.93% | 37 |
|
|
2019
Q3 | $9.98M | Sell |
386,204
-1,544
| -0.4% | -$39K | 1.07% | 35 |
|
|
2019
Q2 | $9.89M | Buy |
387,748
+25,280
| +7% | +$625K | 1.08% | 34 |
|
|
2019
Q1 | $9.48M | Sell |
362,468
-12,914
| -3% | -$317K | 1.03% | 35 |
|
|
2018
Q4 | $8.65M | Sell |
375,382
-202
| -0.1% | -$4.49K | 1.03% | 38 |
|
|
2018
Q3 | $8.85M | Buy |
375,584
+6,740
| +2% | +$164K | 0.99% | 39 |
|
|
2018
Q2 | $8.51M | Sell |
368,844
-17,370
| -4% | -$413K | 1.01% | 40 |
|
|
2018
Q1 | $9.51M | Sell |
386,214
-154
| -0% | -$4.04K | 1.2% | 32 |
|
|
2017
Q4 | $10.4M | Sell |
386,368
-1,010
| -0.3% | -$25.7K | 1.24% | 35 |
|
|
2017
Q3 | $9.33M | Sell |
387,378
-5,174
| -1% | -$117K | 1.17% | 35 |
|
|
2017
Q2 | $8.42M | Buy |
392,552
+3,422
| +0.9% | +$69.1K | 1.13% | 34 |
|
|
2017
Q1 | $6.67M | Buy |
389,130
+28,828
| +8% | +$502K | 0.93% | 38 |
|
|
2016
Q4 | $6.46M | Buy |
360,302
+155,332
| +76% | +$2.82M | 0.87% | 39 |
|
|
2016
Q3 | $4.26M | Buy |
204,970
+187,010
| +1,041% | +$4.64M | 0.6% | 52 |
|
|
2016
Q2 | $483K | Buy |
17,960
+1,636
| +10% | +$44.9K | 0.07% | 103 |
|
|
2016
Q1 | $442K | Buy |
16,324
+3,586
| +28% | +$96.1K | 0.06% | 106 |
|
|
2015
Q4 | $370K | Buy |
+12,738
| New | +$353K | 0.06% | 107 |
|
Other funds holding NVO
DAM
F
D.J. St. Germain's NVO Position: Q1 2026 in Review
D.J. St. Germain increased its Novo Nordisk (NVO) stake by 0.27% in Q1 2026, buying an estimated $10K and bringing the position to 78,744 shares worth $2.89M. The position accounts for 0.11% of the portfolio, ranked #112.
D.J. St. Germain first reported a position in NVO in Q4 2015 and has held it in 41 quarters since. The position peaked at $18.9M in Q2 2023. 1,271 funds tracked by Wall St. Rank hold NVO as of Q1 2026.
- D.J. St. Germain held 78,744 shares of Novo Nordisk worth $2.89M as of Q1 2026.
- D.J. St. Germain bought 211 Novo Nordisk shares in Q1 2026, an estimated $10K.
- Novo Nordisk made up 0.11% of D.J. St. Germain's portfolio in Q1 2026, its #112 holding.
- D.J. St. Germain first reported a position in Novo Nordisk in Q4 2015 and has held it in 41 quarters since.
- D.J. St. Germain's Novo Nordisk position peaked at $18.9M in Q2 2023.
- 1,271 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2026.
Based on D.J. St. Germain's 13F filing for Q1 2026, filed 13 Apr 2026.